Most ALK variants are described as VUS, limiting the
impact of precision oncology. ALK fusions occur in 2.6%% of the lung adenocarcinomas, with EML4 being the most common upstream partner.
Meanwhile, G1202R mutations occur only among 0.07% of the ALK alterations. Heat shock protein and Neuregulin-1 pathway may present additional opportunities for combination targeted therapies in the future for ALK-positive NSCLC. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/S1556-0864(21)01863-3
Authors: A. Desai, T. Mohammed, S. Rakshit, J. Krull
